Ascletis Receives FDA Clearance for ASC30 Phase II Study
Ascletis Pharma Inc. (HKEX: 1672) has recently made significant strides in diabetes treatment by receiving clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This marks a pivotal moment in their ongoing research and development of ASC30, an oral small molecule GLP-1 receptor agonist aimed at treating individuals with type 2 diabetes. The Phase II study will be a comprehensive 13-week, randomized, double-blind, placebo-controlled trial, designed to rigorously assess the efficacy, safety, and tolerability of ASC30.
Study Overview and Goals
The Phase II study is set to evaluate ASC30's performance in approximately 100 participants diagnosed with type 2 diabetes. By assigning participants in a ratio of 2:3:3:2, they will receive either 40 mg, 60 mg, or 80 mg doses of ASC30 tablets, along with corresponding placebo tablets. Each participant will gradually be titrated from a starting dose of 1 mg to their designated dose over the 13 weeks. This design is geared toward determining the mean change in HbA1c levels and comparing treatment effectiveness against the placebo group.
Previous Trials and Positive Outcomes
In prior research, Ascletis conducted a successful 13-week Phase II study that focused on ASC30's effect on individuals with obesity. In that trial, ASC30 achieved clinically significant results, demonstrating a placebo-adjusted weight loss of 7.7%. The findings also indicated improved gastrointestinal tolerability compared to other treatments, with notably fewer adverse effects reported. Ascletis is dedicated to expanding its data collection on ASC30, which shows promise in both obesity and type 2 diabetes management.
Innovative Approach to Diabetes Treatment
ASC30 has been engineered to be a first-of-its-kind investigational small molecule GLP-1 receptor agonist. This means it is designed to be effective in delivering treatment once daily orally, along with options for subcutaneous administration on a monthly or quarterly schedule. These features position ASC30 as a flexible treatment option in the landscape of metabolic disease therapies.
Leadership Vision and Future Plans
Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, articulated the importance of this milestone for the company. He emphasized that the FDA's IND clearance not only validates the company's ongoing research efforts but also opens avenues for ASC30's entry into the substantial diabetes treatment market. The commitment to innovative drug development remains at the forefront as Ascletis aims to provide advanced therapeutic options for conditions like obesity and diabetes.
About Ascletis and Its Technologies
Ascletis Pharma Inc. is committed to advancing healthcare through the development of potential best-in-class and first-in-class therapeutics designed to treat various metabolic diseases. Harnessing proprietary technologies, including Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform technologies, the company has been successful in developing several drug candidates. Their pipeline includes ASC30, as well as other innovative treatments targeted at chronic weight management and other metabolic conditions.
Frequently Asked Questions
What is the purpose of the ASC30 Phase II study?
The ASC30 Phase II study aims to evaluate the efficacy, safety, and tolerability of ASC30 in participants with type 2 diabetes over a 13-week period
How many participants will be enrolled in the study?
Approximately 100 participants diagnosed with type 2 diabetes will be enrolled across multiple sites.
What are the primary endpoints of this study?
The primary endpoint is the mean change from baseline in HbA1c levels at 13 weeks, comparing treatment and placebo groups.
What previous results were seen with ASC30?
In earlier studies, ASC30 demonstrated a statistically significant placebo-adjusted weight loss and favorable gastrointestinal tolerability compared to other treatments.
What technologies does Ascletis utilize in drug development?
Ascletis employs innovative technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platforms to enhance drug discovery and development processes.
